# RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer

Source: https://onco.cc/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/  
OnCo record `paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The combination of the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib shrank tumours in about a third of women with recurrent low-grade serous ovarian cancer and in 44 percent of those with KRAS mutations, leading to the first approval specific to this disease.

## Summary

Phase 2 study of 115 patients with recurrent low-grade serous ovarian cancer treated with avutometinib alone or with defactinib; the combination was selected for expansion.

In the combination arm, objective response was 31 percent overall and 44 percent in KRAS-mutant tumours (17 percent in KRAS wild-type), with median duration of response of 31 months and median progression-free survival of 12.9 months overall; toxicity included creatine kinase elevation, nausea and rash.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2025
- DOI: 10.1200/JCO-25-00112
- Authors: Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al.
- Findings: Objective response 31 percent overall; 44 percent in KRAS-mutant and 17 percent in KRAS wild-type tumours.; Median duration of response 31.1 months.
- What it means: Avutometinib plus defactinib is approved for KRAS-mutant recurrent low-grade serous ovarian cancer, making KRAS testing a routine part of managing the disease; RAMP 301 is comparing it with standard therapy.
- Caveats: Single-arm; approval was accelerated pending the randomised RAMP 301 trial.

## Sources

- J Clin Oncol 2025: https://doi.org/10.1200/JCO-25-00112
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40644648/

## Connected records

- cancers: [Low-grade serous ovarian cancer](https://onco.cc/cancers/low-grade-serous-ovarian-cancer/)
- trials: [RAMP 201](https://onco.cc/trials/ramp-201/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025.json